The major role of human genetic factors in the immune response to infections is now wellestablished, particularly for viral infections. In the context of the COVID-19 pandemic,the following results have identified 1) several inborn errors of immunity (IEI)affecting the response or production of type I interferons (type I IFNs) in around 4% ofadult patients with severe clinical disease, and 2) the presence of type IIFN-neutralizing autoantibodies (auto-Abs) in around 15% of severe cases, and 20% ofdeaths. The investigators would like to carry out a longitudinal immunological andclinical follow-up study on a prospective cohort of patients with either a genetic defectaffecting the type I IFN-dependent immune response, or anti-IFN-I auto-Abs, to monitorthe incidence of infectious and/or autoimmune events in these individuals, the evolutionof neutralizing power, and the kinetics of auto-Abs. This should lead to a betterunderstanding of the prevention and management of these patients.The research design is a national multicenter prospective cohort of adults with 1)anti-IFN-I auto-Abs or 2) IEI- IFN-I, with follow-up from 1 to 4 years. These individualsmay be: 1) patients who have or have had clinical disease (related to COVID-19, otherviral infections, autoimmune disorders); or 2) "healthy" participants (e.g. blood donors,relatives of an IEI patient).Follow-up will include: - yearly visits to the Clinical Investigation Center (CIC) or a clinical department with blood sampling; - specific visit in case of hospitalization for infectious events or adverse effects of vaccination, exacerbation or new diagnosis of auto-immune disease, new diagnosis of cancer, or SARS-CoV-2 infection whether or not patients are admitted to hospital, with blood sampling.In addition, a retrospective "passive" follow-up will be implemented through matchingwith the data from the SNDS (National Health Data System), in order to collect clinicalevents of and healthcare resource consumption. Moreover, matching with controls adultsfrom the national CONSTANCES cohort, not carrying auto-Abs against type I IFNs norIEI-IFN-I, will be performed. (ratio 3:1; matching on age (+/- 5 years), gender andgeographic region of recruitment). Individuals under long-lasting immunosuppressive orimmunomodulatory drugs will not be eligible. Follow-up of controls, which will be carriedout as part of the CONSTANCES cohort, will include web-based questionnaires, every 12months, in addition to linking with SNDS data as already done in this cohort.Inclusion visit:After signing the consent form, the following tests will be performed: - Demographic characteristics (sex, age, country of birth) - Medical history from participant and family member(s) including infectious and auto-immune diseases, cancers and vaccination status and side effects - Blood samples for: - full blood cell count; - classical autoimmune investigations (anti-nuclear, anti-ENA, native anti-DNA, anti- thyroid antibodies, rheumatoid factor); - immunophenotyping*; - auto-Abs against type I IFNs, other cytokines*, or other target proteins* (dosage and neutralization activity); - Genetic explorations by whole-exome or whole-genome sequencing*; - Biobanking (DNA, plasma/sera; cryopreserved peripheral blood mononuclear cells (PBMCs). - these biological analyses will be carried out as part of dedicated COVIFERON RHU5 workpackages.In addition, vaccination against SARS-CoV-2 and influenza will be offered to thesesubjects as a priority, as part of their usual care.Follow-up visits :Annual visits to the CIC : - Medical history since last visit, including infectious, auto-immune and oncologic events, vaccination status and side effects - Blood samples for: - full blood cell count; - classical autoimmune investigation (anti-nuclear, anti-ENA, native anti- DNA, anti-thyroid antibodies, rheumatoid factor); - immunophenotyping; - Auto-Abs against type I IFNs, other cytokines, or other target proteins (dosage and neutralization) - Biobanking (DNA, plasma, cryopreserved peripheral blood mononuclear cells (PBMCs))Additional specific visit in the event of a clinical event of interest, at any timeduring follow-up: - In case of SARS-CoV-2 infection, whatever the severity of the disease: blood sampling for determination and neutralization of type I anti-IFN autoAbs, CBC, and biobanking (plasma and PBMC) and teleconsultation with the CIC in charge of patients, as soon as possible. - In the event of hospitalization for infectious events or exacerbation or new diagnosis of an auto-immune disease: blood sampling for determination and neutralization of anti-IFN-I autoAbs, CBC, and biobanking (plasma and PBMCs) and collection of the hospitalization report in the case report form on a dedicated page.